Controversy
On February 25, 2020, Consumer Reports published an article stating that GoodRx shared user data—specifically, pseudonymized advertising ID numbers that companies use to track the behavior of web users across websites, the names of the drugs that users browsed, and the pharmacies where users sought to fill prescriptions—with Google, Facebook, and around twenty other Internet-based companies.[46] A few days later, GoodRx released a statement saying that it had made changes to prevent user search data on medical conditions and pharmaceuticals from being shared with Facebook.[47]
In March 2020, GoodRx stopped sending data about user prescriptions to Facebook.[48]
On February 1, 2023, the Federal Trade Commission fined GoodRx US$1.5 million for violations of the Breach Notification Rule and the Federal Trade Commission Act for allegedly failing to obtain specific, informed, and unambiguous consent from users before disclosing health-related information[49] to Facebook and Google.[50][51][52]
In November 2024, independent pharmacies filed at least three class action lawsuits against GoodRx and major pharmacy benefit managers. The cases, brought by independent pharmacies in California, Michigan, Pennsylvania, and Rhode Island, allege that GoodRx and the PBMs collaborated to suppress reimbursements for generic prescription drugs.[53] They allege that agreements using GoodRx’s software suppressed reimbursements for generic drugs and violated the Sherman Antitrust Act. The suits claim the practices amount to price fixing which harms small pharmacies while benefiting PBMs and their affiliates.[54]
GoodRx settled both the 2023 FTC action and the 2025 class action lawsuit without admitting wrongdoing.[55][56]
